Gene · 80199
FUZ: fuzzy planar cell polarity protein
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FUZ: fuzzy planar cell polarity protein. Genes, record 80199. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/80199
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9BT04 | Protein fuzzy homolog | 418 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents14
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 46786 | Q9BT04 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1629 | Q9BT04 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1629 | Q9BT04 | Espacenet |
| JP 2024503719 A | 2024-01-26 | 123 | Q9BT04 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 33093 | Q9BT04 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 136064 | Q9BT04 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 227221 | Q9BT04 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 227221 | Q9BT04 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 227221 | Q9BT04 | Espacenet |
| US 7919467 B2 | 2011-04-05 | 1059 | Q9BT04 | Espacenet |
1 to 10 of 14
See all 14 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants837
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FUZ papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| T32AI007245 | Molecular Basis of Viral Infectivity | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| U19AI135995 | Center for Viral Systems Biology (CViSB) | 4 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
| R01HD085901 | Mapping the ciliary interactome, an extensive protein interaction network underlying human ciliopathies | 3 | 2025 |
| R01HL117164 | Development and function in mucociliary epithelia | 3 | 2025 |
| ZIACL002123 | Molecular Immunohematology in Ethiopian Sub-populations | 3 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 2 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 837Source NIH's project files
See all 837 nih grantsPapers1,517
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of Novel Interacting Proteins of FUZ and GPR161. | Proteomics | 2026 | 42400918 | PubTator, text mining | PubMed |
| Substrate selectivity of the human RNA m5C methyltransferase NSUN2. | Nature | 2026 | 42203868 | PubTator, text mining | PubMed |
| Rebuilding the Mucociliary Apparatus in ECRS: TSLP/IL-33 Signaling Synergy and the Residual Molecular Scar of DNASE1L3 Following IL-4/13 Blockade. | Cells | 2026 | 42193919 | PubTator, text mining | PubMed |
| Structural similarity between CD38 and the Duffy antigen as a potential mechanism of attenuated anti-Fy antibody reactivity with soluble CD38. | Br J Haematol | 2026 | 42178236 | PubTator, text mining | PubMed |
| Phenotypic Expansion and Molecular Implications in Recessive FUZ -Related Ciliopathy. | Clin Genet | 2026 | 41952398 | PubTator, text mining | PubMed |
| The CDKL5 kinase undergoes liquid-liquid phase separation driven by a serine-rich C-terminal region. | Life Sci Alliance | 2026 | 41807047 | PubTator, text mining | PubMed |
| DFT guided design of novel quinone bioisosteres as inhibitors of the clathrin N-terminal domain-amphiphysin protein-protein interaction. Dihydroquinazolin-4(1H)-ones and quinazolin-3(4H)-ones. | Eur J Med Chem | 2026 | 41806571 | PubTator, text mining | PubMed |
| Toll-like receptor signaling outcome is determined by the stoichiometry of the endogenous TRIFosome. | Sci Adv | 2026 | 41790885 | PubTator, text mining | PubMed |
| AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in Mice. | Vaccines (Basel) | 2026 | 41746060 | PubTator, text mining | PubMed |
| Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer. | J Natl Cancer Cent | 2026 | 41738039 | PubTator, text mining | PubMed |
1 to 10 of 1,517
See all 1,517 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/80199
GET https://conductscience.org/api/genes/v1/80199/patents